Nexstim published its January to June 2026 report on August 14. Net sales were EUR 5.23 million, up 16.1% from a year earlier, and EBITDA was EUR 0.26 million, the fourth consecutive half-year of positive EBITDA. The net result was a loss of EUR 0.86 million, which included about EUR 0.6 million of one-off financing costs.
The report recaps two FDA clearances for the NBS 6 system in March 2026: adult obsessive-compulsive disorder, and major depressive disorder in adolescents aged 15 to 21. Nexstim says 55 systems with therapy applications are in use in the United States and 145 worldwide.
Therapy revenue slipped 2.1% in the half, while research and neuroscience revenue rose sharply, helped by a EUR 0.8 million license fee tied to an agreement with Sinaptica Therapeutics. Nexstim also reported a EUR 5 million investment from Eiffel Investment Group and Brainlab.
Source
Reporting based on coverage from Nexstim (via Inderes). This article is editorial summary intended for general information; it is not medical advice.
